Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Albumin-bound sirolimus - CSPC ZhongQi Pharmaceutical Technology

Next Previous
X
Search
Drug Profile

Albumin-bound sirolimus - CSPC ZhongQi Pharmaceutical Technology

Alternative Names: Albumin-bound rapamycin - CSPC ZhongQi Pharmaceutical Technology

Latest Information Update: 25 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC ZhongQi Pharmaceutical Technology
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Perivascular epithelioid cell tumours
  • Phase I Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 23 Nov 2022 Phase-I/II clinical trials in Perivascular epithelioid cell tumours (Metastatic disease; Late-stage disease) in China (IV) (NCT05625919)
  • 28 Dec 2021 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (IV) (NCT05125523)
  • 18 Nov 2021 CSPC ZhongQi Pharmaceutical Technology plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (NCT05125523)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top